[ | E-mail ] Contact: ESMO Press Officemedia@esmo.orgEuropean Society for Medical Oncology@myesmo Preliminary data from a phase III trial suggest drug is well tolerated and leads to a sustained response in patients who have progressed after ipilimumab therapy The monoclonal antibody…
Source:Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma
Monday, September 29, 2014
Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment